Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Geoffrey Gabriel

Psychosomatic Medicine Greenville, SC Medical Doctor

NPI 1306946454 CMS profile 330954

414 Pettigru St, Suite C, Greenville, SC 29601

Open in the dashboard

General payments

$1,046

64 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Geoffrey Gabriel of Greenville, SC is reported in the CMS Open Payments database as having received $1,046 across 64 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Psychosomatic Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $137 7
2023 General $330 21
2022 General $148 10
2021 General $241 14
2020 General $158 10
2019 General $32 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Geoffrey Gabriel
  • Psychosomatic Medicine median
  • Middle half of Psychosomatic Medicine
  • National median

In program year 2025, general payments to Geoffrey Gabriel were reported at $0. Among 72 Psychosomatic Medicine profiles paid that year, the median was $152 and the middle half received between $47 and $428.

Show as a table
Year Geoffrey Gabriel Psychosomatic Medicine median Middle half National median
2019 $32 $125 $51–$524 $163
2020 $158 $117 $29–$251 $114
2021 $241 $123 $33–$366 $132
2022 $148 $107 $37–$450 $149
2023 $330 $131 $57–$397 $160
2024 $137 $122 $27–$293 $164
2025 $0 $152 $47–$428 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Otsuka America Pharmaceutical, Inc. $213 15 payments
  2. Bausch Health US, LLC $164 10 payments
  3. AbbVie, Inc. $158 9 payments
  4. Avanir Pharmaceuticals, Inc. $144 10 payments
  5. Lundbeck LLC $142 7 payments
  6. Axsome Therapeutics, Inc. $91 4 payments
  7. Merck Sharp & Dohme Corporation $65 4 payments
  8. Allergan Inc. $53 4 payments
  9. Eisai Inc. $18 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $1,046 64 payments
Products named General payments · program years 2019–2024
  1. APLENZIN $164 10 payments
  2. VRAYLAR Neuroscience $158 9 payments
  3. NUEDEXTA pseudobulbar affect (PBA) $144 10 payments
  4. REXULTI Psychiatry $142 7 payments
  5. NUEDEXTA Neurology $134 10 payments
  6. REXULTI Psychiatry $79 5 payments
  7. Auvelity $74 3 payments
  8. BELSOMRA $65 4 payments
  9. VRAYLAR Neuroscience $38 3 payments
  10. Dayvigo $18 1 payment
  11. Other $31 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

247

Median for Neuropsychiatry: 88

Drug cost

$54,018

Median for Neuropsychiatry: $2,689

Branded share of claims

33.6%

Median for Neuropsychiatry: 16.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Auvelity Dextromethorphan Hbr/Bupropion Brand 19 $17,152
Trintellix Vortioxetine Hydrobromide Brand 33 $15,100
Belsomra Suvorexant Brand 20 $8,481
Vyvanse Lisdexamfetamine Dimesylate Brand 11 $7,840
Vilazodone Hcl Generic 31 $3,449
Minocycline Hcl Generic 16 $531
Liothyronine Sodium Generic 12 $417
Quetiapine Fumarate Generic 15 $224
Propranolol Hcl Generic 12 $205
Lamotrigine Generic 13 $178

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,891 Part D prescribers listed as Neuropsychiatry; they describe a distribution and say nothing about conduct.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Auvelity
  • Axsome Therapeutics, Inc. $52
$52 19 —
VRAYLAR
  • AbbVie, Inc. $38
$38 — —
APLENZIN
  • Bausch Health US, LLC $17
$17 — —
Sunosi
  • Axsome Therapeutics, Inc. $16
$16 — —
NUEDEXTA
  • Otsuka America Pharmaceutical, Inc. $14
$14 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

64 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychosomatic Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record